ClinicalTrials.gg
Active, not recruitingNCT06044649Updated Nov 13, 2026

Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain

An interventional study of Cognitive Behavioral Therapy and Acceptance and Commitment Therapy in Chronic Pain, Neck Pain and Back Pain, sponsored by Rush University Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Rush University Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Study documents postedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Enrollment
82nd of 1,092
408 · median 60
Started
2023
with 116 others
No phase
803 of 1,283
168 open now
Primary completion
2027-02
later than 151 of 347 live
Registered
1,006th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 82nd largest by enrollment of the 1,092 interventional ones that give a count, is one of 117 that started in 2023, is one of 803 with no phase, reaches primary completion later than 151 of the 347 other live ones, and was the 1,006th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

Chronic musculoskeletal pain (CP) is a major public health concern. Psychosocial treatments have been shown to be efficacious when compared to largely inert control conditions, but they are characterized by modest effects on primary outcomes. One strategy to boost efficacy is to increase our understanding of treatment mediators. Studies of mediators that directly compare different treatments with each other are needed to determine which mediators are treatment-specific, which are shared across treatments, and which contribute the most to clinical outcomes. Another strategy is to identify the patient characteristics that moderate treatment responses. Research is needed that is guided by theoretical models and that tests moderators across multiple treatments. Identifying subgroups of patients more likely to respond to one or another treatment can advance precision medicine by informing a priori patient-treatment matches that can optimize treatment effects. To accomplish these goals, the authors will conduct a randomized clinical trial to compare the mediators and moderators of the clinical effects of Cognitive-Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Emotional Awareness and Expression Therapy (EAET) on adults with chronic spinal (axial) pain. Following baseline assessment of outcome variables as well as potential mediators and moderators, 460 participants will be randomized to CBT, ACT, EAET, or treatment-as-usual control (TAU). The three treatments will be conducted as individual therapy provided weekly for 8 weeks via telehealth. The researchers will conduct weekly assessments of both potential mediators and outcomes, as well as post-treatment and 6-month follow-up assessments. The goal of the study is to identify the most powerful treatment mechanisms - specific and shared -- and reveal for whom the mediator-outcome pathways are strongest.This project can increase the effects of our psychosocial chronic pain treatments by identifying the most effective treatment mechanisms and by informing patient-treatment matches that can optimize treatment effects.

Read the detailed description

Chronic musculoskeletal pain (CP) is a major public health concern. A number of psychosocial treatments have emerged in recent decades to help address this problem. These interventions have been shown to be efficacious when compared to largely inert control conditions; however, recent meta-analyses indicate that most of these treatments are characterized by modest effects on primary outcomes. This is a critical shortcoming of these otherwise promising approaches. Rather than attempting to boost efficacy only by developing new and hopefully more powerful interventions, we can also look within our already proven treatments for ways to enhance the magnitude of treatment effects. One strategy is to increase our understanding of treatment mediators. Studies of mediators that directly compare different treatments with each other are needed to determine which mediators are treatment-specific, which are shared across treatments, and which contribute the most to clinical outcomes. The findings from such research could be used to inform adaptations to existing treatment that enhance their benefits. A second strategy for increasing the beneficial effects of existing treatments is to identify the patient characteristics that moderate treatment responses. Research is needed that is guided by theoretical models and that tests moderators across multiple treatments. Identifying subgroups of patients more likely to respond to one or another treatment can advance precision medicine by informing a priori patient-treatment matches that can optimize treatment effects. To accomplish these goals, we will conduct a randomized clinical trial to compare the mediators and moderators of the clinical effects of Cognitive-Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Emotional Awareness and Expression Therapy (EAET) on adults with chronic spinal (axial) pain. Following baseline assessment of outcome variables as well as potential mediators and moderators we will randomize 460 participants to CBT, ACT, EAET, or treatment-as-usual control (TAU). The three treatments will be conducted as individual therapy provided weekly for 8 weeks via telehealth. We will conduct weekly assessments of both potential mediators and outcomes, as well as post-treatment and 6-month follow-up assessments. In addition to comparing the three treatments to each other (and TAU) for overall efficacy, we focus on two specific aims: Aim 1 is to identify mediators that are specific to treatments and those that are shared across treatments. Aim 2 is to identify baseline moderators of specific treatments and general predictors across treatments. This project can increase the effects of our psychosocial chronic pain treatments by identifying the most powerful treatment mechanisms - specific and shared -- and revealing for whom the mediator-outcome pathways are strongest. Via increased understanding of mediator and moderators, more effective pain treatment approaches can be developed, tested, and implemented.

03

Conditions studied

  • Chronic Pain
  • Neck Pain
  • Back Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Back/neck is primary pain location (e.g., back/neck pain greater than leg pain)
  • Pain for at least 3 months and experienced 4 or more days/week for the past 6 months
  • Pain intensity last week is >= 3 (0 to 10 rating scale)
  • Pain interference last week is >= 3 (0 to 10 rating scale)
  • At least age 18
  • Lives in United States
  • Fluent in English
  • Has personal computer/tablet and internet access
  • Able to attend weekly sessions
  • Willing to be randomized
  • Seeking to improve their pain-related status via a psychological therapy

Exclusion criteria

Exclusion Criteria:

Past 2 years (treated for or having experienced):

  • Complex regional pain syndrome
  • Epilepsy/seizure disorder
  • disease
  • Liver disease
  • Cancer
  • Heart disease
  • Substance dependence or use disorder
  • Schizophrenia or other psychotic disorder
  • Bipolar disorder
  • Obsessive-compulsive disorder
  • Borderline personality disorder
  • Suicide attempt or suicide intention or impulse

Also:

  • Major medical procedure scheduled within next 9 months
  • Applied for/ litigating for pain-related disability/worker's compensation (past year).
  • Major life event/stressor in past 6 months
  • Cognitive impairment (screener score \<=4)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    Cognitive Behavioral Therapy

    8-session, individual, Cognitive Behavioral Therapy delivered remotely by skilled CBT therapists

    Behavioral: Cognitive Behavioral Therapy

  • Experimental
    Acceptance and Commitment Therapy

    8-session, individual, Acceptance and Commitment Therapy delivered remotely by skilled ACT therapists

    Behavioral: Acceptance and Commitment Therapy

  • Experimental
    Emotional Awareness and Expression Therapy

    8-session, individual, Emotional Awareness and Expression Therapy delivered remotely by skilled EAET

    Behavioral: Emotional Awareness and Expression Therapy

  • Other
    Treatment As Usual

    In this control condition, participants will engage in their usual care for neck/back pain with no additional experimental intervention

    Other: Treatment as Usual

Interventions

  • BehavioralCognitive Behavioral Therapy

    CBT endorses a pain management model and teaches people skills to cope with chronic pain.

    Also known as: CBT for chronic pain

  • BehavioralAcceptance and Commitment Therapy

    ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.

    Also known as: ACT for chronic pain

  • BehavioralEmotional Awareness and Expression Therapy

    EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.

    Also known as: EAET for chronic pain

  • OtherTreatment as Usual

    Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.

    Also known as: TAU

06

What researchers measure

Primary outcomes

  1. Brief Pain Inventory (BPI) - Pain Severity

    4-item measure of pain severity over past week (range 0 to 10; higher scores = worse pain severity)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  2. Patient-Reported Outcome Measurement Information System (PROMIS) - Pain Interference - Short Form 8a

    8-item measure of pain interference over past week (range1 to 5; higher scores = more pain interference)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

Secondary outcomes

  1. Patient Global Impression of Change

    1-item measure of overall health change since the start of the study (range 1 to 7; higher scores = more health improvement)

    Time frame: Weekly during treatment to post-treatment and 6-month follow-up

  2. Patient-Reported Outcome Measurement Information System (PROMIS) - Physical Function - Short Form 10a

    4-item measure of current physical function (range 1 to 5; higher scores = poorer physical function)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  3. Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Anxiety - Short Form

    4-item measure of anxiety symptoms in the past week (range 1 to 5; higher scores = more anxiety symptoms)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  4. Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Depression - Short Form

    4-item measure of depression symptoms in the past week (range 1 to 5; higher scores = more depression symptoms)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  5. Patient Health Questionnaire - Depression

    8-item measure of depression symptoms in the past week (range 0 to 3; higher scores = more depression symptoms)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  6. Patient-Reported Outcome Measurement Information System (PROMIS) - Fatigue - Short Form

    4-item measure of fatigue in the past week (range 1 to 5; higher scores = more fatigue)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  7. Patient-Reported Outcome Measurement Information System (PROMIS) - Sleep Disturbance - Short Form

    4-item measure of sleep disturbance in the past week (range 1 to 5; higher scores = more sleep disturbance)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  8. Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Anger - Short Form 5a

    5-item measure of anger in the past week (range 1 to 5; higher scores = more anger)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  9. Positive and Negative Affect Schedule (PANAS) - Positive Affect - Short Form

    5-item measure of positive affect in the past week (range 1 to 5; higher scores = more positive affectivity)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  10. Posttraumatic Stress Disorder Checklist (PCL) - Short Form

    5-item measure of trauma symptoms in the past week (range 1 to 4; higher scores = worse PTSD symptoms)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  11. Pain Stages of Change Questionnaire (PSOCQ): Preparation and action

    13-item measure on current readiness to adopt self-management for pain, Preparation and Action items only (range 1 to 5; higher scores = more ready to change)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  12. Opioid Use

    1-item measure on opioid use in past 7 days (range 1 to 7; higher scores = more days)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  13. Employment

    3-item measure on current employment (options for current status and qualitative responses)

    Time frame: Baseline to post-treatment and 6-month follow-up

  14. Post-Treatment Satisfaction Questionnaire

    8-item measure on patient post-treatment satisfaction (range 1 to 10; higher scores = more satisfied - also included qualitative responses)

    Time frame: Post-Treatment to 6-Month Follow-Up

  15. Levels of Emotional Awareness Scale (LEAS) - Forms A and B

    10-item measure of current emotional awareness (includes qualitative responses); responses coded for levels of emotional awareness; higher = greater awareness; Form A baseline and Form B at post-treatment

    Time frame: Baseline

  16. Other Pain Treatments and Health Care Use

    2-item measure of health care currently, the past 6 months, and the past 4 weeks (2 items with yes/no responses and remaining range 0 to 4; higher scores = more treatment)

    Time frame: Baseline to post-treatment and 6-month follow-up

  17. Inventory of Interpersonal Problems (IIP)

    32-item measure of current interpersonal problems (range 0 to 4; higher scores = more interpersonal problems)

    Time frame: Baseline to post-treatment and 6-month follow-up

  18. American College of Rheumatology (ACR) Fibromyalgia Diagnostic Criteria - 2011

    8-item measure on fibromyalgia symptoms in the past week (items with yes/no responses, a checklist, and remaining range 0 to 3; higher scores = worse fibromyalgia symptoms)

    Time frame: Baseline to post-treatment and 6-month follow-up

  19. Psychological Flexibility Scale (PSYFlex)

    6-item measure of psychological flexibility in the past week (range 0 to 5; higher scores = higher psychological flexibility)

    Time frame: Baseline to post-treatment and 6-month follow-up

  20. The Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Tool - Part II

    9-item measure on substance use in the past week (yes/no responses); higher scores = more use

    Time frame: Baseline to post-treatment and 6-month follow-up

  21. Posttraumatic Stress Disorder Checklist (PCL)

    20-item measure of PTSD symptoms in the past month (range 0 to 4; higher scores = worse PTSD symptoms)

    Time frame: Baseline to post-treatment and 6-month follow-up

Other outcomes

  1. Pain Catastrophizing Scale (PCS)-short form

    Potential Mediator; 6-item measure of pain catastrophizing (range 0 to 4; higher scores = higher pain catastrophizing)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  2. Pain Self-Efficacy Questionnaire (PSEQ) - Short Form

    Potential Mediator; 4-item measure of current pain self-efficacy (range 0 to 6; higher scores = higher pain self-efficacy)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  3. Survey of Pain Attitudes (SOPA): Pain Control, Disability, Harm, Emotion subscales

    Potential Mediator; 4, 2-item measures of current pain attitudes (range 0 to 4; higher scores = more of that construct)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  4. Behavioral Activation for Depression (BADS) - Short Form

    Potential Mediator; 9-item measure of behavioral activation for depression in the past week (range 0 to 6; higher scores = higher behavioral activation)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  5. Self-Compassion Scale (SCS) - Short Form

    Potential Mediator; 12-item measure of situational self-compassion (range 1 to 5; higher scores = less self-compassion)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  6. Chronic Pain Acceptance Questionnaire (CPAQ)

    Potential Mediator; 8-item measure of current chronic pain acceptance (range 0 to 6; higher scores = more chronic pain acceptance)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  7. Chronic Pain Values Inventory (CPVI)

    Potential Mediator; 6-item measure of current values (checklist responses)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  8. Emotional Approach Coping Scale (EAC) - Short Form

    Potential Mediator; 4-item measure of emotional approach coping (range 1 to 4; higher scores = higher emotional approach coping)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  9. Emotional Breakthrough Inventory (EBI)

    Potential Mediator; 6-item measure of emotional breakthroughs in the past week (range 0 to 6; higher scores = more emotional breakthroughs)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  10. Psychological Insight Questionnaire (PIQ)

    Potential Mediator; 6-item measure of psychological insight in the past week (range 0 to 5; higher scores = more psychological insight)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  11. Brain and Psychological Attributions for Pain

    Potential Mediator; 9-item measure of current belief of brain and psychological attributions for pain (range 0 to 4; higher scores = higher belief in brain and psychological attributions for pain)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  12. Pain Anxiety Symptom Scale (PASS)

    Potential Mediator; 4-item measure of current pain anxiety symptoms (range 0 to 5; higher scores = worse pain anxiety symptoms)

    Time frame: Baseline to post-treatment and 6-month follow-up, and weekly during treatment

  13. Adverse Events

    Potential Mediator; 2-item measure of adverse events in the past week and past 6 months (checklist responses)

    Time frame: Weekly during treatment to post-treatment and 6-month follow-up

  14. Working Alliance Inventory (WAI) - Patient

    Potential Mediator; 6-item measure of current working alliance (range 0 to 5; higher scores = better working alliance)

    Time frame: Weekly during treatment to post-treatment for three treatment arms only

  15. Working Alliance Inventory (WAI) - Therapist - Short Form

    Potential Mediator; 6-item measure of current working alliance (range 0 to 5; higher scores = better working alliance)

    Time frame: Weekly during treatment to post-treatment for three treatment arms only

  16. Therapist Checklist of Patient Engagement and Homework

    Potential Mediator; 4-item measure on current patient engagement (range 0 to 8; higher scores = more patient engagement)

    Time frame: Weekly during treatment to post-treatment for three treatment arms only

  17. Treatment Expectancy and Credibility Questionnaire

    Potential Mediator; 8-item measure on current treatment expectancy and credibility (range 0 to 10; higher scores = better treatment expectancy)

    Time frame: Weekly during treatment to post-treatment for three treatment arms only

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 39 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Feb 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 21, 2023
StartActual
Nov 15, 2023
Primary completionEst.
Feb 28, 2027was Aug 2026
CompletionEst.
Feb 28, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 30, 2026→Feb 28, 2027
Nov 13, 2026
Documents
Show all 1 update
  1. Nov 13, 2026
    Primary completion Aug 30, 2026→Feb 28, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06044649
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Nov 15, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

John W Burns, PhD
principal investigator · Rush University Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion